The purified IL-15 was then conjugated to a cytotopic peptide to allow anchoring of IL-15 to cell membranes (cyto-IL-15) and its activity and efficacy were investigated in vitro and in vivo in a prostate cancer murine model. This evidence concerns the gene IL15 and prostate cancer.